Coverart for item
The Resource Immunomodulating drugs for the treatment of cancer, [edited by] Asher A.A. Chanan-Khan, MBBS, Associate Professor of Medicine, Department of Medicine, State University of New York at Buffalo, Attending Physician & Associate Professor of Oncology, Division of Lymphoma/Myeloma, Roswell Park Cancer Institute, Buffalo, New York

Immunomodulating drugs for the treatment of cancer, [edited by] Asher A.A. Chanan-Khan, MBBS, Associate Professor of Medicine, Department of Medicine, State University of New York at Buffalo, Attending Physician & Associate Professor of Oncology, Division of Lymphoma/Myeloma, Roswell Park Cancer Institute, Buffalo, New York

Label
Immunomodulating drugs for the treatment of cancer
Title
Immunomodulating drugs for the treatment of cancer
Statement of responsibility
[edited by] Asher A.A. Chanan-Khan, MBBS, Associate Professor of Medicine, Department of Medicine, State University of New York at Buffalo, Attending Physician & Associate Professor of Oncology, Division of Lymphoma/Myeloma, Roswell Park Cancer Institute, Buffalo, New York
Contributor
Editor
Subject
Language
eng
Summary
Immunomodulatory (IMiDs) drugs are a new class of anticancer agents that has made a tremendous impact on the treatment of patients with various malignant diseases, including blood cancers and several cancers of the solid organs. Their popularity in prescribing is based on several important characteristics including: (1) oral bioavailability, (2) non-chemotherapeutic, (3) extremely well-tolerated in all age groups, (4) ability to activate patient's own immune response against cancer, (5) ease of combination with other agents such as chemotherapy resulting in higher responses as well as (6) variability of anticancer activity and a number of cancers. While there is a lot of literature published on these agents, there is no textbook that provides a comprehensive resource for clinicians and researchers regarding these agents and their rapidly emerging role in cancer medicine
Cataloging source
DNLM/DLC
Dewey number
616.99/4061
Illustrations
  • illustrations
  • plates
Index
index present
LC call number
RC271.I45
LC item number
I462 2011
Literary form
non fiction
Nature of contents
bibliography
NLM call number
QZ 267
http://library.link/vocab/relatedWorkOrContributorName
Chanan-Khan, Asher A. A.
http://library.link/vocab/subjectName
  • Cancer
  • Biological response modifiers
  • Neoplasms
  • Adjuvants, Immunologic
  • Adjuvants, Immunologic
  • Immunotherapy
  • Neoplasms
Label
Immunomodulating drugs for the treatment of cancer, [edited by] Asher A.A. Chanan-Khan, MBBS, Associate Professor of Medicine, Department of Medicine, State University of New York at Buffalo, Attending Physician & Associate Professor of Oncology, Division of Lymphoma/Myeloma, Roswell Park Cancer Institute, Buffalo, New York
Instantiates
Publication
Bibliography note
Includes bibliographical references and index
Carrier category
volume
Carrier category code
  • nc
Carrier MARC source
rdacarrier.
Content category
text
Content type code
  • txt
Content type MARC source
rdacontent.
Contents
Introduction to the immunomodulatory agents for the treatment of malignant conditions -- Preclinical development -- Mechanism of action of the immunomodulating drugs (IMiDs) compounds -- Clinical development -- Overview: clinical impact of IMiDs in oncology -- Thalidomide for relapsed or refractory myeloma -- Role of IMiDs as initial therapy for multiple myeloma -- Role of immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma in elderly patients -- IMiDs as maintenance therapy in multiple myeloma -- Lenalidomide for the treatment of relapsed or refractory multiple myeloma -- IMiDs and stem cell transplantation in multiple myeloma -- Immunomodulating drugs in Waldenstrõm's macroglobulinemia -- Lenalidomide for the treatment of myelodysplastic syndromes -- Thalidomide and lenalidomide for the treatment of primary myelofibrosis -- Immunomodulatory drugs for the treatment of chronic lymphocytic leukemia -- Lenalidomide in combination with other novel agents: a new dimension in myeloma therapeutics -- Lenalidomide for non-hodgkin's lymphoma -- Clinical efficacy of immunomodulatory drugs in amyloidosis -- Immunomodulating drugs for the treatment of prostate cancer -- Pomalidomide in cancer therapy -- Complications -- IMiDs-associated toxicities and their management -- Toxicity associated with the immunomodulating agents in patients with chronic lymphocytic leukemia
Control code
664677363
Dimensions
29 cm
Edition
1st edition.
Extent
xiv, 299 pages, 4 unnumbered pages of plates
Isbn
9781605473338
Isbn Type
(hardback : alk. paper)
Lccn
2010050171
Media category
unmediated
Media MARC source
rdamedia.
Media type code
  • n
Other physical details
illustrations (some color)
System control number
(OCoLC)664677363
Label
Immunomodulating drugs for the treatment of cancer, [edited by] Asher A.A. Chanan-Khan, MBBS, Associate Professor of Medicine, Department of Medicine, State University of New York at Buffalo, Attending Physician & Associate Professor of Oncology, Division of Lymphoma/Myeloma, Roswell Park Cancer Institute, Buffalo, New York
Publication
Bibliography note
Includes bibliographical references and index
Carrier category
volume
Carrier category code
  • nc
Carrier MARC source
rdacarrier.
Content category
text
Content type code
  • txt
Content type MARC source
rdacontent.
Contents
Introduction to the immunomodulatory agents for the treatment of malignant conditions -- Preclinical development -- Mechanism of action of the immunomodulating drugs (IMiDs) compounds -- Clinical development -- Overview: clinical impact of IMiDs in oncology -- Thalidomide for relapsed or refractory myeloma -- Role of IMiDs as initial therapy for multiple myeloma -- Role of immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma in elderly patients -- IMiDs as maintenance therapy in multiple myeloma -- Lenalidomide for the treatment of relapsed or refractory multiple myeloma -- IMiDs and stem cell transplantation in multiple myeloma -- Immunomodulating drugs in Waldenstrõm's macroglobulinemia -- Lenalidomide for the treatment of myelodysplastic syndromes -- Thalidomide and lenalidomide for the treatment of primary myelofibrosis -- Immunomodulatory drugs for the treatment of chronic lymphocytic leukemia -- Lenalidomide in combination with other novel agents: a new dimension in myeloma therapeutics -- Lenalidomide for non-hodgkin's lymphoma -- Clinical efficacy of immunomodulatory drugs in amyloidosis -- Immunomodulating drugs for the treatment of prostate cancer -- Pomalidomide in cancer therapy -- Complications -- IMiDs-associated toxicities and their management -- Toxicity associated with the immunomodulating agents in patients with chronic lymphocytic leukemia
Control code
664677363
Dimensions
29 cm
Edition
1st edition.
Extent
xiv, 299 pages, 4 unnumbered pages of plates
Isbn
9781605473338
Isbn Type
(hardback : alk. paper)
Lccn
2010050171
Media category
unmediated
Media MARC source
rdamedia.
Media type code
  • n
Other physical details
illustrations (some color)
System control number
(OCoLC)664677363

Library Locations

    • J. Otto Lottes Health Sciences LibraryBorrow it
      1 Hospital Dr, Columbia, MO, 65201, US
      38.939544 -92.328377
Processing Feedback ...